Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

Type II Diabetes Clinical Trial

Official title:

A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Potential Efficacy of PS1 in Subjects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05176210
• Other study ID #: PS1-01
• Status: Recruiting
• Phase: Phase 1
• Start date: December 22, 2023
• Est. completion date: July 2025

Study information

• Verified date: April 2024
• Source: Pharmasaga Co. Ltd.
• Contact: Yuyu Chung, Master
• Phone: +886-2-2793-8665
• Email: pm[@]pharmasaga.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, double-blind, placebo-controlled, randomized, single- and multiple-ascending dose study to evaluate new study intervention, PS1. PS1 is a potential blood glucose control medication, which is developed by Pharmasaga Co. Ltd. planned for treating type II diabetes mellitus (T2DM). This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), food effect and potential efficacy of PS1 in subjects.

Description:

This first-in-human Phase I study consists of a single ascending-dose (SAD) portion, a food effect (FE) portion, and a multiple ascending-dose (MAD) portion, aiming to evaluate the safety, tolerability, pharmacokinetics, food effect and potential efficacy of PS1 in healthy subjects.

A randomized, double-blinded, placebo-controlled study design will be applied for the SAD portion with three SAD dose cohorts-25 mg (Cohort 1), 50 mg (Cohort 2), and 75 mg (Cohort 3). An eligible subject in this portion will receive a single dose of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.

In FE portion, only one cohort (Cohort 4) is assigned. The FE cohort (Cohort 4) will use the same study design as the SAD cohorts. An eligible subject in this portion will receive a single dose of 50 mg PS1 or Placebo tablets in a fasted condition on Day 1 and be followed for 7 days.

Four cohorts are assigned in the MAD portion: 25 mg/day (Cohort 5 & 7) and 50 mg/day (Cohort 6 & 8) in healthy volunteers and participants respectively. Only the dose level of MAD lower than the maximum tolerated dose (MTD) of SAD portion can be activated (If 50 mg was determined as the MTD of SAD, only cohort 5 & 7 could be activated). An eligible subject will receive PS1 or Placebo tablets once daily in a fed condition for 14 days & 28 days in healthy volunteers and participants respectively and be followed for additional 7 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 64
• Est. completion date: July 2025
• Est. primary completion date: July 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

For all cohorts, a subject is eligible for the study if all of the following apply:

1. Both genders aged 18 to 80 years, inclusive at screening

2. Body mass index (BMI) between 18.5 and 40.0 kg/m2

3. Negative test for hepatitis B surface antigen (HBsAg), Anti-HCV antibody, and human immunodeficiency virus (HIV) at screening

4. Is willing to follow the trial life style instruction and protocol procedure

5. Able to understand and sign the informed consent form.

Inclusion criteria applied for healthy subjects (Cohorts 1~6)

6. Overtly healthy subject, who is considered to be generally healthy based on medical history, vital signs, laboratory tests, 12-lead EKG, and physical examination, as judged by the investigator

7. With HbA1c value of < 6.5% and fasting plasma glucose < 110 mg/dL at Screening

8. With estimated glomerular filtration rate (eGFR) > 80 ml/min

Inclusion criteria applied for T2DM patients (Cohort 7 and 8)

9. Diagnosis of T2DM

10. T2DM treated with diet and exercise alone currently, for at least 2 weeks prior to Screening

11. With HbA1c level between 6.5% to 9.0% and fasting plasma glucose level between 130 mg/dL to 250 mg/dL at Screening

12. With estimated glomerular filtration rate (eGFR) > 60 ml/min

13. For patients taking medication for other chronic disease, the medication should be on a stable dose for at least 4 weeks prior to Screening, and should not be a strong CYP enzyme inhibitor or inducer

Exclusion Criteria:

For all cohorts, a subject meeting any of the following exclusion criteria will be excluded from study participation.

1. History of Type I diabetes mellitus

2. Under the systemic treatment of any prescription medication or over-the-counter (OTC) medication that may interfere with the safety or PK assessment judged by the investigator within 7 days before Screening

3. Received strong CYP enzyme inhibitor or inducer within 14 days before Screening

4. Received any vaccination within 14 days before Screening

5. Has required insulin therapy within the past 12 weeks

6. Known hypersensitivity to any of the components of PS1 tablet

7. History of major clinically significant hematological, renal, respiratory, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, musculoskeletal, immune, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within 3 months of Screening that may significantly alter the biomarker panel, require receiving any systemic medications, or interfere with the interpretation of data, as judged by the investigator

8. History of pancreatitis

9. Serum amylase > 1.5 × Upper Limit of Normal (ULN) or lipase > 1.5 × ULN

10. Clinically significant ECG abnormality at Screening

11. History of cancer (malignancy) or have ever received any anti-cancer therapy

12. Regular smoker Regular smoker is defined as who smokes every day (= 1 cigarette/day in average in the past 8 weeks of Screening)

13. Consumed greater than 3 units of alcoholic beverages per day in average for the past 4 weeks before Screening One unit is equivalent to one can of beer (20% alcohol; about 45 mL)

14. Received any investigational therapy from another clinical study or underwent any major surgeries within the last 12 weeks prior to Screening.

15. Took glucose-lowering medications within the last 2 weeks prior to Screening

16. Received any systemic steroids (inhaled and intranasal steroids are permitted) or other immunosuppressive medications within 4 weeks prior to Screening

17. Have ever received cell therapy or organ transplantation

18. Other conditions not suitable for participating in this study as judged by the investigator

19. Any conditions that forbid the completion of study procedures due to the local regulatory restrictions

20. Female subject of childbearing potential who:

• Is lactating; or

• Has a positive pregnancy test result at Screening; or

• Refuses to adopt at least one form of birth control (refer to Section 5.3) from signing informed consent to the end of the study.

21. Male subject with a female spouse/partner who is of childbearing potential refuses to adopt at least one form of birth control (refer to Section 5.3) from signing informed consent to the end of the study.

Exclusion criteria applied for healthy subjects (Cohorts 1~6):

22. History of type II diabetes mellitus

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type II Diabetes

Intervention

Drug:
• PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
• Placebo
Placebo will be provided as a 120 mg tablet.

Locations

Country	Name	City	State
Taiwan	Mingche Liu	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Pharmasaga Co. Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose-limiting toxicity (DLT) during the DLT observation period	DLT is defined as: (1) any adverse event (AE) = Grade 3 (CTCAE v5.0) or (2) Grade 2 AE that does not resolve to grade 1 or less within 72 hours, that occurs in the DLT observation period and is causally related (possibly, probably, or definitely related) to the test article judged by the investigator.	Day 1~ Day 8 (SAD cohort); Day 1~ Day 35 (MAD cohort)
Secondary	Incidence of adverse events (AEs) and serious adverse events (SAEs)	All adverse events (AEs) will be assessed for severity by the investigator based on NCI-CTCAE v5.0	SAD, FE: up to 4 weeks; MAD: up to 8 weeks
Secondary	Number of participants with abnormalities in Vital signs	Number of participants with abnormal systolic/diastolic blood pressure (in mmHg), respiratory rate, pulse rate (in beat per minute, bpm), and body temperature (in ?)	SAD, FE: Baseline,1~2 weeks; MAD: Baseline,1~6 weeks
Secondary	Number of participants with abnormalities in Laboratory examinations	Number of participants with abnormal Hematology (hemoglobin, hematocrit, RBC, platelet, WBC, WBC differentials (neutrophils, eosinophils, basophils, lymphocytes, monocytes), MCV, MCH, MCHC), biochemistry (HbA1c, fasting plasma glucose, albumin, alkaline phosphatase, ALT, AST, BUN, creatinine, cholestero1, ?-GT, total protein, total bilirubin, direct bilirubin, triglyceride, amylase, lipase, calcium, sodium, potassium, chloride), and urinalysis (pH, protein, glucose, bilirubin, urobilinogen, ketone body, specific gravity, occult blood, RBC, WBC, creatinine, ratio of albumin/creatinine) results	SAD, FE: Baseline,1~2 weeks; MAD: Baseline,1~6 weeks
Secondary	Acute kidney injury (AKI) marker	Urine samples will be collected for analyzing acute kidney injury (AKI) markers	SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks
Secondary	Number of participants with abnormalities in 12-lead electrocardiogram (EKG)	Number of participants with abnormal Ventricular rate, PR interval, QRS interval, and QT interval	SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks
Secondary	Number of participants with abnormalities in Physical examination	Number of participants with abnormal Physical examination results, including general appearance, skin, eyes, ears, nose, throat, head and neck (including thyroid), heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal, neurological system, and other body systems	SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks
Secondary	Pharmacokinetics (PK) of PS1	AUC_Area under the serum concentration-time profile	Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only)
Secondary	Pharmacokinetics (PK) of PS1	Cmax_The peak post-dose concentration	Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only)
Secondary	Pharmacokinetics (PK) of PS1	Tmax_Time at which Cmax is observed	Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only)
Secondary	Pharmacokinetics (PK) of PS1	T1/2_Terminal phase elimination half-life	Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only)
Secondary	Pharmacokinetics (PK) of PS1	MRT_Mean Residence Time	Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only)
Secondary	Pharmacokinetics (PK) of PS1	CL/F_Apparent Clearance	Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only)
Secondary	Pharmacokinetics (PK) of PS1	Volume of distribution	Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only)
Secondary	Pharmacokinetics (PK) of PS1	Rac_Accumulation ratio	Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only)
Secondary	Potential efficacy (For Cohort 7 and 8 only)	Changes from baseline of fasting plasma glucose (FPG) at each post-treatment visit; Changes from baseline of C-peptide at each post-treatment visit; Changes from baseline of hemoglobin A1c (HbA1c) at Visit 10 and Visit 11.	MAD: Baseline, 1~6 weeks
Secondary	Exploratory Endpoints (For MAD only)	Changes from baseline of serum PDIA4	MAD: Baseline, 1~6 weeks